F.D.A. Panel Gives the Nod to R.S.V. Shot to Protect Infants
Summary A Food and Drug Administration (F.D.A.) advisory panel has recommended approval for a monoclonal antibody shot designed to prevent respiratory syncytial virus (R.S.V.) in infants and vulnerable toddlers. Sanofi and AstraZeneca
